Pancreatic cancer is a devastating disease. It is the fourth leading cause of cancer-related death in Germany. The incidence in 2003/2004 was 16 cases per 100.000 inhabitants. Of all carcinomas, pancreatic cancer has the highest mortality rate, with one- and five-year survival rates of 25% and less than 5%, respectively, regardless of the stage at diagnosis. These low survival rates demonstrate…
Gemcitabine is an active agent for treatment of advanced nonsmall cell lung cancer (NSCLC). Weekly treatment with singleagent gemcitabine has shown response rates of 20% to 26%. This Phase II trial was conducted to determine the efficacy and safety of 1000 mg/m2 gemcitabine administered weekly for 3 weeks followed by 1 week or rest (28-day cycle). Patients were required to have histologic evide…
A two- drug platinum- based regimensis the standard first- line treatment for inoperable non- smallcell lung cancer /NSCLC/ patients with perfomance status/PS/ 0-2. The aim of this study was to evaluate the efficacyand safety of chemotherapy combination Gemcitabine- cis-Platinum in patients with advanced NSCLC
Among patients with macroscopic complete removal of pancreatic cancer, the use of adjuvant gemcitabine for 6 months compared with observation alone resulted in increased overall survival as well as disease-free survival. These findings provide strong support for the use of gemcitabine in this setting
Although the number of antihyperglycemic agents has expanded signifcantly, sulfonylureas (in particular gliclazide) remain an important option because of a variety of patient and health system factors. The large, real world, observational, and international EASYDia trial evaluated the efectiveness of gliclazide modifed release (MR) 60 mg in individuals with type 2 diabetes with a broad range …
Many anti-diabetic drugs with different mechanisms of action are now available for treatment of type 2 diabetes mellitus. Sulfonylureas have been extensively used for treatment of type 2 diabetes for nearly 50 years and, even in our times, are widely used for treatment of this devastating chronic illness. Here, we review some of the available data on sulfonylureas, evaluating their mechanism of…
Minoxidil was first introduced as an antihypertensive medication and the discovery of its common adverse event, hypertrichosis, led to the development of a topical formulation for promoting hair growth. To date, topical minoxidil is the mainstay treatment for androgenetic alopecia and is used as an off-label treatment for other hair loss conditions. Despite its widespread application, the exac…
A new, novel product, Cynatine HNS, was evaluated for its effects as a supplement for improving various aspects of hair and nails in a randomized, double-blind, placebo-controlled clinical trial.
Emerging evidence suggests that trace elements such as zinc (Zn2+) and copper (Cu2+) are essential cofactor for multiple enzymes and have functional activities within hair follicles. So its deficiencies may cause hair loss
It is well known that some trace elements such as zinc and copper play a significant role in many forms of hair loss. However, the effect of zinc and copper in the pathogenesis of hair loss is still unknown